Enliven Therapeutics Inc (NASDAQ: ELVN) established initial surge of 10.39% at $17.74, as the Stock market unbolted on Thursday, before settling in for the price of $16.07 at the close. Taking a more long-term approach, ELVN posted a 52-week range of $13.30-$30.03.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
In the past 5-years timespan, the Healthcare sector firm’s annual sales growth was 0.00%. Meanwhile, its Annual Earning per share during the time was 19.02%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -26.56%. This publicly-traded company’s shares outstanding now amounts to $49.04 million, simultaneously with a float of $32.21 million. The organization now has a market capitalization sitting at $870.49 million. At the time of writing, stock’s 50-day Moving Average stood at $18.48, while the 200-day Moving Average is $22.41.
Enliven Therapeutics Inc (ELVN) Ownership Facts and Figures
Sometimes it is also beneficial to study the sentiment of large-scale investors towards the stock of the Enliven Therapeutics Inc industry. Enliven Therapeutics Inc’s current insider ownership accounts for 34.36%, in contrast to 73.73% institutional ownership. According to the most recent insider trade that took place on May 27 ’25, this organization’s CHIEF FINANCIAL OFFICER sold 3,250 shares at the rate of 16.18, making the entire transaction reach 52,593 in total value, affecting insider ownership by 23,000.
Enliven Therapeutics Inc (ELVN) Earnings and Revenue Records
Enliven Therapeutics Inc’s EPS decrease for this current 12-month fiscal period is -26.56% and is forecasted to reach -2.80 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will decrease by -21.18% through the next 5 years, which can be compared against the 19.02% growth it accomplished over the previous five years trading on the market.
Enliven Therapeutics Inc (NASDAQ: ELVN) Trading Performance Indicators
Let’s observe the current performance indicators for Enliven Therapeutics Inc (ELVN). It’s Quick Ratio in the last reported quarter now stands at 21.06. The Stock has managed to achieve an average true range (ATR) of 1.34.
In the same vein, ELVN’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -1.93, a figure that is expected to reach -0.58 in the next quarter, and analysts are predicting that it will be -2.80 at the market close of one year from today.
Technical Analysis of Enliven Therapeutics Inc (ELVN)
Now, what If we examine the latest scores posted by [Enliven Therapeutics Inc, ELVN]. During the last 5-days, its volume was lower the volume of 0.28 million it reported in year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 26.23% While, its Average True Range was 1.26.
Raw Stochastic average of Enliven Therapeutics Inc (ELVN) in the period of the previous 100 days is set at 36.79%, which indicates a major fall in contrast to 37.48% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 75.33% that was higher than 67.66% volatility it exhibited in the past 100-days period.
